Ultragenyx Pharmaceutical Inc.

Equities

RARE

US90400D1081

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
45.14 ^USD	+2.85%		+10.42%	-5.60%

Jun. 21	Ultragenyx Pharmaceutical Inc. Approves Ratification of Selection of Ernst & Young LLP as the Independent Registered Public Accounting Firm	CI
Jun. 14	Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	MT

Ultragenyx Pharmaceutical Inc. Approves Ratification of Selection of Ernst & Young LLP as the Independent Registered Public Accounting Firm

June 21, 2024 at 04:06 pm EDT

Ultragenyx Pharmaceutical Inc. held its Annual Meeting of Stockholders on June 18, 2024. At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

Latest news about Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc. Approves Ratification of Selection of Ernst & Young LLP as the Independent Registered Public Accounting Firm	Jun. 21	CI
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating	Jun. 14	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	Jun. 14	MT
Ultragenyx Pharmaceutical Prices $350 Million Offering	Jun. 14	MT
Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025	Jun. 12	MT
Ultragenyx Pharmaceutical Launches Equity Offering	Jun. 12	MT
Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment	Jun. 12	DJ
Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA	Jun. 12	CI
Sector Update: Health Care Stocks Ease Late Afternoon	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate	Jun. 12	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	Jun. 12	MT
Sector Update: Health Care	Jun. 12	MT
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study	Jun. 12	CI
Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate	Jun. 12	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM	Jun. 11
Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56	Jun. 06	MT
Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating	May. 31	MT
Stifel Adjusts Price Target on Ultragenyx Pharmaceutical to $127 From $124, Maintains Buy Rating	May. 31	MT
Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating	May. 31	MT
Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating	May. 31	MT
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	May. 30
Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia	May. 30	CI
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer	May. 14	MT
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM	May. 14

Chart Ultragenyx Pharmaceutical Inc.

Duration

Period

More charts

Company Profile

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Ultragenyx Pharmaceutical Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

45.14 USD

Average target price

89.95 USD

Spread / Average Target

+99.27%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ULTRAGENYX PHARMACEUTICAL INC.	-5.60%	4.09B
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs